Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
HB9 CRISPR/Cas9 KO Plasmid (m): sc-420869
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- HB9 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the HB9 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: HB9 Antibody (F-5): sc-515769
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HB9 CRISPR/Cas9 KO Plasmid (m) | sc-420869 | 20 µg | $397.00 |
Overview
Mnx1 (HB9) encodes a homeobox transcription factor that is essential for ventral spinal cord development and the specification and maturation of somatic motor neurons. HB9 participates in transcriptional programs that coordinate neuronal subtype identity, axon guidance, and neuromuscular connectivity through regulation of lineage-specific gene expression. In the pancreas, Mnx1 also contributes to endocrine lineage decisions, linking it to developmental pathways that shape organogenesis and cell fate determination. Altered MNX1 expression or function has been associated with motor neuron developmental phenotypes and has been studied in the context of congenital neurological and pancreatic developmental disorders, as well as lineage dysregulation in cancer biology.
HB9 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Mnx1 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Mnx1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Mnx1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish HB9 protein expression.
This CRISPR knockout system enables efficient generation of Mnx1-deficient cell models for investigation of HB9 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Mnx1 exon(s) critical for HB9 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Mnx1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by HB9 CRISPR/Cas9 KO Plasmid (m) and HB9 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Mnx1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by HB9 HDR Plasmid (m) and HB9 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Mnx1 homology arms to support homology-directed repair at defined Mnx1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.